Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jun 7;15(12):1453.
doi: 10.3390/diagnostics15121453.

Pituitary Apoplexy in a Child with Short Stature and Possible Recent SARS-CoV-2 Infection

Carmen Gabriela Barbu  1   2 , Luminita Nicoleta Cima  1   2 , Marian Andrei  2 , Simona Vasilache  3 , Mihaela Țarnă  2 , Ileana Olguta Rizea  4 , Carmen Sorina Martin  1   2 , Anca Elena Sîrbu  1   2 , Simona Fica  1   2
Affiliations
Case Reports

Pituitary Apoplexy in a Child with Short Stature and Possible Recent SARS-CoV-2 Infection

Carmen Gabriela Barbu et al. Diagnostics (Basel). .

Abstract

Background and Clinical Significance: Pituitary apoplexy is an extremely rare condition in children and adolescents with a rapid onset due to acute hemorrhage, infarction, or both in the pituitary gland. Most frequently, pituitary apoplexy is an asymptomatic or subclinical entity. Few cases of pituitary apoplexy with concurrent SARS-CoV-2 infection or COVID-19 vaccination have been reported. Case Presentation: We present the case of a 13-year-8-month-old boy who presented in our pediatric endocrinology department for the evaluation of short stature. He was previously diagnosed with secondary hypothyroidism and was treated with levothyroxine. At admission, clinical examination revealed a height of 141 cm (-2.68 SD/-2.4 SD corrected for mid-parental height), normal weight (60th centile), Tanner-stage G2P1, and delayed bone age. Basal IGF1 was normal, but the tests performed to assess the GH reserve confirmed the GH deficiency (peak GH value 3.11 ng/mL after clonidine/0.95 ng/mL after insulin). The brain MRI revealed a subacute pituitary hemorrhage. Thrombophilia and coagulopathies were excluded by further testing. Anti-SARS-CoV-2 (anti-S-protein IgG) antibodies (>200 BAU/mL) were compatible with COVID-19 infection, indicating a possible association between these two entities. At 3-month follow-up, physical examination showed a 3 cm height gain and advancing pubertal development (G4P2). Newer MRI found changes consistent with resolving hemorrhage. The patient was provided immediately with recombinant human GH and aromatase inhibitor therapy to maximize GH treatment response. During follow-up, the rGH dose was adjusted based on IGF1 values, and after 3 years and 10 months, rGH treatment was stopped, reaching a height of 172.3 cm (-0.51 SD) and surpassing the initial prediction of 164.5 cm. Conclusions: Pituitary apoplexy, an even rarer complication in the pediatric population, may be associated with SARS-CoV-2 infection. Further studies are necessary to better understand the intertwining of those conditions.

Keywords: COVID-19; aromatase inhibitor therapy; pituitary apoplexy; short stature.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
November 2021 MRI scan: (a) T1 TSE (turbo spin echo) sagittal; (b) T1 TSE FS (fat-suppressed) coronal; (c) FLAIR sagittal; (d) T2 TSE coronal.
Figure 2
Figure 2
Growth history during follow-up with a measurement error range of 0.5 cm [20].
Figure 3
Figure 3
March 2025 MRI scan: (a) FLAIR coronal; (b) T2 TSE coronal; (c) T1 TSE coronal; (d) T1 TSE FS coronal +Gd; (e) T1 TSE sagittal; (f) T1 TSE sagittal +Gd.
See this image and copyright information in PMC

Similar articles

  • Antibody tests for identification of current and past infection with SARS-CoV-2.
    Fox T, Geppert J, Dinnes J, Scandrett K, Bigio J, Sulis G, Hettiarachchi D, Mathangasinghe Y, Weeratunga P, Wickramasinghe D, Bergman H, Buckley BS, Probyn K, Sguassero Y, Davenport C, Cunningham J, Dittrich S, Emperador D, Hooft L, Leeflang MM, McInnes MD, Spijker R, Struyf T, Van den Bruel A, Verbakel JY, Takwoingi Y, Taylor-Phillips S, Deeks JJ; Cochrane COVID-19 Diagnostic Test Accuracy Group. Fox T, et al. Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2. Cochrane Database Syst Rev. 2022. PMID: 36394900 Free PMC article.
  • Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.
    Dinnes J, Sharma P, Berhane S, van Wyk SS, Nyaaba N, Domen J, Taylor M, Cunningham J, Davenport C, Dittrich S, Emperador D, Hooft L, Leeflang MM, McInnes MD, Spijker R, Verbakel JY, Takwoingi Y, Taylor-Phillips S, Van den Bruel A, Deeks JJ; Cochrane COVID-19 Diagnostic Test Accuracy Group. Dinnes J, et al. Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3. Cochrane Database Syst Rev. 2022. PMID: 35866452 Free PMC article.
  • Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
    Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, Spijker R, Hooft L, Emperador D, Domen J, Tans A, Janssens S, Wickramasinghe D, Lannoy V, Horn SRA, Van den Bruel A; Cochrane COVID-19 Diagnostic Test Accuracy Group. Struyf T, et al. Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
  • Sertindole for schizophrenia.
    Lewis R, Bagnall AM, Leitner M. Lewis R, et al. Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
  • Measures implemented in the school setting to contain the COVID-19 pandemic.
    Krishnaratne S, Littlecott H, Sell K, Burns J, Rabe JE, Stratil JM, Litwin T, Kreutz C, Coenen M, Geffert K, Boger AH, Movsisyan A, Kratzer S, Klinger C, Wabnitz K, Strahwald B, Verboom B, Rehfuess E, Biallas RL, Jung-Sievers C, Voss S, Pfadenhauer LM. Krishnaratne S, et al. Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029. Cochrane Database Syst Rev. 2022. Update in: Cochrane Database Syst Rev. 2024 May 2;5:CD015029. doi: 10.1002/14651858.CD015029.pub2. PMID: 35037252 Free PMC article. Updated.
See all similar articles

References

    1. Semple P.L., De Villiers J.C., Bowen R.M., Lopes M.B.S., Laws E.R. Pituitary Apoplexy: Do Histological Features Influence the Clinical Presentation and Outcome? J. Neurosurg. 2006;104:931–937. doi: 10.3171/jns.2006.104.6.931. - DOI - PubMed
    1. Bonicki W., Kasperlik-Załuska A., Koszewski W., Zgliczyński W., Wisławski J. Pituitary Apoplexy: Endocrine, Surgical and Oncological Emergency. Incidence, Clinical Course and Treatment with Reference to 799 Cases of Pituitary Adenomas. Acta Neurochir. 1993;120:118–122. doi: 10.1007/BF02112028. - DOI - PubMed
    1. Jankowski P.P., Crawford J.R., Khanna P., Malicki D.M., Ciacci J.D., Levy M.L. Pituitary Tumor Apoplexy in Adolescents. World Neurosurg. 2015;83:644–651. doi: 10.1016/j.wneu.2014.12.026. - DOI - PubMed
    1. Biousse V., Newman N.J., Oyesiku N.M. Precipitating Factors in Pituitary Apoplexy. J. Neurol. Neurosurg. Psychiatry. 2001;71:542–545. doi: 10.1136/jnnp.71.4.542. - DOI - PMC - PubMed
    1. Randeva H.S., Schoebel J., Byrne J., Esiri M., Adams C.B.T., Wass J.A.H. Classical Pituitary Apoplexy: Clinical Features, Management and Outcome. Clin. Endocrinol. 1999;51:181–188. doi: 10.1046/j.1365-2265.1999.00754.x. - DOI - PubMed

Publication types

LinkOut - more resources